Sonoma Pharmaceuticals expands dental care line

Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn® technology based stabilised hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, has launched two new dental products.

OroGenix Oral Hygiene Rinse is Sonoma’s second dental product in the United States (US), and was developed with its partner Gabriel Science, LLC. Additionally, in Switzerland, Sonoma and its partner, Medical Systems Solutions, have launched Microdacyn® Oral Care for both professional and consumer use.

After successfully launching Endocyn® for root canal irrigation in December 2020, Sonoma’s second dental product in the US is an oral hygiene rinse. OroGenix Oral Hygiene Rinse uses Sonoma’s patented Microcyn® technology to cleanse teeth, gums, and mouth.

In Europe, Microdacyn60® Oral Care is intended to combat oral and pharyngeal infections and inflammation, and reduce pain and coughing. Sonoma’s dental products do not stain the teeth, and are manufactured using the safe and effective evidence-based Microcyn® technology.

“We believe the OroGenix Oral Hygiene Rinse and the Microcyn family of hypochlorous acid products will help dentists and their patients achieve healthy gums, teeth, and oral cavity,” said Dr Mark Fontenot, managing member of Gabriel Science, LLC.

“Microdacyn60® Oral Care offers a superior alternative for oral and throat care. Not only in dentistry, but also in general oral and pharyngeal care such as intubated patients, we see the great benefits of Microdacyn60 Oral Care as an alternative for widely used chlorhexidine-based products,” commented Mr Edgar Sommer, general manager of Medical System Solutions.

“We are pleased to bring the oral rinse to dental offices in the US, and for both professional and consumer use in Europe. Gabriel Science and Medical System Solutions are ideal partners for advancing our dental and oral care line of products,” said Bruce Thornton, chief operating officer of Sonoma Pharmaceuticals. “Our proprietary Microcyn technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety.”